دورية أكاديمية
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
| العنوان: | Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen |
|---|---|
| المؤلفون: | Giacchetti, S., Porcher, R., Lehmann-Che, J., Hamy, A. S., Roquancourt, A., De, Cuvier, C., Cottu, P. H., Bertheau, P., Albiter, M., Bouhidel, F., Coussy, F., Extra, J. M., Marty, M., de Thé, Hugues, Espie, M. |
| المساهمون: | Collège de France - Chaire Oncologie cellulaire et moléculaire, Génomes, biologie cellulaire et thérapeutiques (GenCellDis (U944 / UMR7212)), Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité) |
| المصدر: | ISSN: 0007-0920. |
| بيانات النشر: | HAL CCSD Cancer Research UK |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | [SDV.CAN]Life Sciences [q-bio]/Cancer |
| الوصف: | International audience ; BACKGROUND: Triple-negative (TN) breast cancers exhibit major initial responses to neoadjuvant chemotherapy, but generally have a poor outcome. Because of the lack of validated drug targets, chemotherapy remains an important therapeutic tool in these cancers. METHODS: We report the survival of two consecutive series of 267 locally advanced breast cancers (LABC) treated with two different neoadjuvant regimens, either a dose-dense and dose-intense cyclophosphamide-anthracycline (AC) association (historically called SIM) or a conventional sequential association of cyclophosphamide and anthracycline, followed by taxanes (EC-T). We compared pathological responses and survival rates of these two groups and studied their association with tumours features. RESULTS: Although the two regimens showed equivalent pathological complete response (pCR) in the whole population (16 and 12%), the SIM regimen yielded a non-statistically higher pCR rate than EC-T (48% vs 24%, P=0.087) in TN tumours. In the SIM protocol, DFS was statistically higher for TN than for non-TN patients (P=0.019), although we showed that the TN status was associated with an increased initial risk of recurrence in both regimens. This effect gradually decreased and after 2 years, TN was associated with a significantly decreased likelihood of relapse in SIM-treated LABC (hazard ratio (HR)=0.25 (95% CI: 0.07-0.86), P=0.028). CONCLUSIONS: AC dose intensification treatment is associated with a very favourable long-term survival rate in TN breast cancers. These observations call for a prospective assessment of such dose-intense AC-based regimens in locally advanced TN tumours. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-03653840; https://hal.science/hal-03653840Test; https://hal.science/hal-03653840/documentTest; https://hal.science/hal-03653840/file/bjc201481.pdfTest; PUBMEDCENTRAL: PMC3960631 |
| DOI: | 10.1038/bjc.2014.81 |
| الإتاحة: | https://doi.org/10.1038/bjc.2014.81Test https://hal.science/hal-03653840Test https://hal.science/hal-03653840/documentTest https://hal.science/hal-03653840/file/bjc201481.pdfTest |
| حقوق: | http://creativecommons.org/licenses/byTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.BA2E4BFE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/bjc.2014.81 |
|---|